SZSE:301096 (China)
Â
Class A
Â¥
39.96
(-1.04%)
Nov 28
Business Description
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd
ISIN : CNE1000056N5
Share Class Description:
SZSE:301096: Class ACompare
Compare
Traded in other countries / regions
301096.China IPO Date
2021-12-20Description
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a pharmaceutical technology research and development company. The company's business covers drug discovery, pharmaceutical research, clinical research, and registration application.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.77 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 2.87 | |||||
| Interest Coverage | 29.37 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 3.63 | |||||
| Beneish M-Score | -1.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 54.2 | |||||
| 3-Year EBITDA Growth Rate | 51.7 | |||||
| 3-Year EPS without NRI Growth Rate | 48.4 | |||||
| 3-Year FCF Growth Rate | -30.5 | |||||
| 3-Year Book Growth Rate | 80.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 19.02 | |||||
| Future 3-5Y Total Revenue Growth Rate | 21.55 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.64 | |||||
| 9-Day RSI | 45.94 | |||||
| 14-Day RSI | 47.39 | |||||
| 6-1 Month Momentum % | -27.52 | |||||
| 12-1 Month Momentum % | -32.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.94 | |||||
| Quick Ratio | 1.75 | |||||
| Cash Ratio | 0.56 | |||||
| Days Inventory | 111.29 | |||||
| Days Sales Outstanding | 98.73 | |||||
| Days Payable | 202.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.74 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| Forward Dividend Yield % | 0.74 | |||||
| 5-Year Yield-on-Cost % | 0.76 | |||||
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -7.32 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.22 | |||||
| Operating Margin % | 23.19 | |||||
| Net Margin % | 20.69 | |||||
| FCF Margin % | -67.63 | |||||
| ROE % | 7.8 | |||||
| ROA % | 5.71 | |||||
| ROIC % | 9.09 | |||||
| ROC (Joel Greenblatt) % | 11 | |||||
| ROCE % | 7.33 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.39 | |||||
| Forward PE Ratio | 12.88 | |||||
| PE Ratio without NRI | 17.86 | |||||
| PEG Ratio | 0.33 | |||||
| PS Ratio | 4.19 | |||||
| PB Ratio | 1.58 | |||||
| Price-to-Tangible-Book | 1.63 | |||||
| EV-to-EBIT | 21.66 | |||||
| EV-to-EBITDA | 21.66 | |||||
| EV-to-Revenue | 4.44 | |||||
| EV-to-FCF | -6.69 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.67 | |||||
| Price-to-Graham-Number | 1.14 | |||||
| Price-to-Net-Current-Asset-Value | 7.27 | |||||
| Earnings Yield (Greenblatt) % | 4.62 | |||||
| FCF Yield % | -15.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,025.121 | ||
| EPS (TTM) (Â¥) | 1.96 | ||
| Beta | 0 | ||
| Volatility % | 53.03 | ||
| 14-Day RSI | 47.39 | ||
| 14-Day ATR (Â¥) | 1.753381 | ||
| 20-Day SMA (Â¥) | 40.9405 | ||
| 12-1 Month Momentum % | -32.33 | ||
| 52-Week Range (Â¥) | 33.57 - 77.78 | ||
| Shares Outstanding (Mil) | 109.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd Frequently Asked Questions
What is Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096)'s stock price today?
The current price of SZSE:301096 is ¥39.96. The 52 week high of SZSE:301096 is ¥77.78 and 52 week low is ¥33.57.
When is next earnings date of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096)?
The next earnings date of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) is .
Does Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) pay dividends? If so, how much?
The Dividend Yield %  of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) is 0.74% (As of Today), Highest Dividend Payout Ratio of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) was 0.38. The lowest was 0.13. And the median was 0.36. The  Forward Dividend Yield % of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) is 0.74%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers